Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | CD22 | P20273 | 1/20 | 0.45 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19006137 | 0.95 | SENP1 (0.50) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL19006139 | 0.83 | OPRM1 (0.57) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL22473633 | 0.76 | OPRM1 (0.64) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL13735950 | 0.76 | OPRM1 (0.66) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL19134196 | 0.75 | OPRM1 (0.63) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL18694532 | 0.75 | OPRM1 (0.63) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL20896592 | 0.75 | OPRM1 (0.61) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL19134215 | 0.75 | OPRM1 (0.50) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL20896670 | 0.75 | CA12 (0.61) | OPRM1PKMCA12CA1CA2 | |
| SCHEMBL20904552 | 0.75 | CA12 (0.61) | OPRM1PKMCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809562-B2 | NAT10 modulators for treating or preventing laminopathies, aging and cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | LMNB2, LMNB1, LMNA | OPRM1 4606/4885PKM 1564/4885CA12 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.